Matching articles for "Aptivus"
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • February 1, 2014; (Issue 138)
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Dolutegravir (Tivicay) for HIV
The Medical Letter on Drugs and Therapeutics • September 30, 2013; (Issue 1426)
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years...
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir
and elvitegravir were approved earlier.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • June 1, 2011; (Issue 106)
Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others. Resistance testing is...
Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others. Resistance testing is now recommended when antiretroviral drugs are started. Increases in HIV RNA levels ("viral load") while on therapy may indicate development of drug resistance, requiring further testing and a change in the treatment regimen. Antiretroviral drugs interact with each other and with many other drugs; complete information on these interactions is available at www.aidsinfo.nih.gov.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • February 1, 2009; (Issue 78)
New guidelines for use of antiretroviral agents have been published, with a shift towards earlier and more continuous treatment. HIV infection is treated with combinations of antiretroviral drugs depending on...
New guidelines for use of antiretroviral agents have been published, with a shift towards earlier and more continuous treatment. HIV infection is treated with combinations of antiretroviral drugs depending on the patientÆs HIV RNA levels ("viral load") and CD4 cell count. Increases in viral load while on therapy may indicate development of drug resistance, requiring further testing and a change in treatment regimen. Resistance testing is now recommended when a patient is first seen, regardless of when therapy will be started.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • October 1, 2006; (Issue 50)
The approval of new drugs and continuing concerns about drug toxicity and resistance have prompted new antiretroviral treatment guidelines. Resistance testing is not recommended before starting antiretroviral...
The approval of new drugs and continuing concerns about drug toxicity and resistance have prompted new antiretroviral treatment guidelines. Resistance testing is not recommended before starting antiretroviral therapy. HIV infection is treated with combinations of antiretroviral drugs while monitoring the patient's HIV RNA levels ("viral load") and CD4 cell count. Increases in viral load while on therapy may indicate development of drug resistance requiring further testing and a change in treatment regimen.
Tipranavir (Aptivus) for HIV
The Medical Letter on Drugs and Therapeutics • October 10, 2005; (Issue 1219)
Tipranavir (Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir (Norvir). The combination is indicated for use with other...
Tipranavir (Aptivus - Boehringer Ingelheim), a new protease inhibitor, has received accelerated approval from the FDA. It must be given with ritonavir (Norvir). The combination is indicated for use with other antiretrovirals to treat HIV infection in highly treatment-experienced adults who have ongoing viral replication or in those with HIV strains known to be resistant to multiple protease inhibitors.